Nisa Investment Advisors LLC Takes Position in Endo International PLC (NASDAQ:ENDP)
Nisa Investment Advisors LLC bought a new position in Endo International PLC (NASDAQ:ENDP) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 42,300 shares of the company’s stock, valued at approximately $507,000.
Other hedge funds have also made changes to their positions in the company. Macquarie Group Ltd. increased its position in Endo International PLC by 132.1% in the fourth quarter. Macquarie Group Ltd. now owns 6,500 shares of the company’s stock worth $107,000 after buying an additional 3,700 shares during the period. Americafirst Capital Management LLC purchased a new position in Endo International PLC during the first quarter worth approximately $286,000. Hartford Investment Management Co. purchased a new position in Endo International PLC during the first quarter worth approximately $1,363,000. Nationwide Fund Advisors increased its position in Endo International PLC by 400.0% in the first quarter. Nationwide Fund Advisors now owns 343,874 shares of the company’s stock worth $3,838,000 after buying an additional 275,101 shares during the period. Finally, First Quadrant L P CA purchased a new position in Endo International PLC during the first quarter worth approximately $24,556,000. 93.00% of the stock is currently owned by institutional investors and hedge funds.
Shares of Endo International PLC (NASDAQ ENDP) traded down 2.64% during midday trading on Thursday, reaching $7.73. The company had a trading volume of 6,403,968 shares. The company’s market capitalization is $1.73 billion. The firm’s 50 day moving average price is $11.15 and its 200-day moving average price is $11.62. Endo International PLC has a 12 month low of $7.63 and a 12 month high of $24.93.
Endo International PLC (NASDAQ:ENDP) last released its quarterly earnings results on Tuesday, August 8th. The company reported $0.93 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.19. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. The business had revenue of $875.73 million for the quarter, compared to analysts’ expectations of $832.66 million. During the same period in the prior year, the firm earned $0.86 earnings per share. Endo International PLC’s revenue was down 4.9% compared to the same quarter last year. Analysts anticipate that Endo International PLC will post $3.52 earnings per share for the current fiscal year.
WARNING: This article was originally published by Watch List News and is owned by of Watch List News. If you are reading this article on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/nisa-investment-advisors-llc-takes-position-in-endo-international-plc-nasdaqendp/1471238.html.
A number of equities analysts recently commented on the company. William Blair reiterated a “market perform” rating on shares of Endo International PLC in a research note on Wednesday, June 14th. Stifel Nicolaus downgraded Endo International PLC from a “buy” rating to a “hold” rating and decreased their price target for the stock from $22.00 to $15.00 in a research note on Friday, June 9th. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $9.00 price target (down from $15.00) on shares of Endo International PLC in a research note on Wednesday. Vetr upgraded Endo International PLC from a “strong sell” rating to a “sell” rating and set a $11.34 price target for the company in a research note on Wednesday, May 17th. Finally, Deutsche Bank AG set a $13.00 price target on Endo International PLC and gave the stock a “buy” rating in a research note on Wednesday. Three investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and five have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $15.54.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Want to see what other hedge funds are holding ENDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Endo International PLC (NASDAQ:ENDP).
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.